Home/Radiomer Therapeutics/Sougata Dey, PhD

SD

Sougata Dey, PhD

Director of Chemistry

Radiomer Therapeutics

Therapeutic Areas

Radiomer Therapeutics Pipeline

Drug	Indication	Phase
Lead Program (undisclosed)	Oncology	Pre-clinical

Leadership Team at Radiomer Therapeutics

Atul Varadhachary, MD, PhD

Chief Executive Officer

Mark Worscheh, MBA

Chief Financial Officer

Philip Breitfeld, MD

Chief Medical Officer

Michael J. Heffernan, PhD, PE

Vice President of Operations

View full Radiomer Therapeutics profile